Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Change in Receivables (2016 - 2026)

Cytosorbents filings provide 15 years of Change in Receivables readings, the most recent being $137000.0 for Q4 2025.

  • On a quarterly basis, Change in Receivables fell 87.44% to $137000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$423000.0, a 124.59% decrease, with the full-year FY2025 number at -$423000.0, down 124.59% from a year prior.
  • Change in Receivables hit $137000.0 in Q4 2025 for Cytosorbents, up from -$303000.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $1.4 million in Q2 2023 to a low of -$1.3 million in Q3 2024.
  • Median Change in Receivables over the past 5 years was $53967.5 (2021), compared with a mean of $120523.0.
  • Biggest five-year swings in Change in Receivables: skyrocketed 752.71% in 2022 and later tumbled 701.71% in 2023.
  • Cytosorbents' Change in Receivables stood at -$698683.0 in 2021, then skyrocketed by 161.32% to $428400.0 in 2022, then crashed by 183.49% to -$357670.0 in 2023, then skyrocketed by 405.03% to $1.1 million in 2024, then plummeted by 87.44% to $137000.0 in 2025.
  • The last three reported values for Change in Receivables were $137000.0 (Q4 2025), -$303000.0 (Q3 2025), and -$336889.0 (Q2 2025) per Business Quant data.